ClinicalTrials.gg
Status unknownNCT00652184Updated Oct 7, 2008

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

A Phase 2 interventional study of ARYS-01 (sorivudine) cream 3% or placebo cream and placebo in Herpes Zoster and Postherpetic Neuralgia, sponsored by aRigen Pharmaceuticals, Inc.. Status unknown at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-10-07.

Sponsored by aRigen Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2008), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Herpes Zoster with a site in United States — 5 open to participants now, 9 under way, 2 of them phase 3. Herpes Zoster · United States.

Planned enrollment
30th of 85
300 · median 150
Started
2008
with 3 others
Phase 2
29 of 95
1 open now
Registered
24th of 95
by date

Among the 95 studies in Herpes Zoster with a site in United States, this one is the 30th largest by planned enrollment of the 85 interventional ones that give a count, is one of 4 that started in 2008, is one of 29 in phase 2, and was the 24th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

5 of the 95 studies in Herpes Zoster with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Herpes Zoster with a site in United States, or all of them as a file.
02

Study summary

A multi-center, randomized, 4-arm, placebo-controlled, double-blind efficacy study of ARYS-01 (sorivudine) cream 3%.

Read the detailed description

More than 95% of people are infected with varicella Zoster virus (VZV) at one time of life or another. Primary VZV infection manifests as varicella (chicken pox). The virus then establishes a latent infection of the sensory ganglia from which it may reactivate years later to produce the clinical syndrome of Herpes Zoster (shingles). The initial cutaneous VZV lesions are pruritic, erythematous macules; and the lesions progress through maculopapular stage to vesicular, ulceration and crusting phases. The crusting phase signals the beginning of the healing process, and begins with clouding of the vesicular fluid, within about 24 to 48 h after the appearance of each lesion. This is a Phase 2 study to assess: 1) the overall benefit of ARYS-01 (sorivudine) cream 3% vs. Placebo cream (with immediate or delayed use of Valaciclovir therapy) on Herpes Zoster rash healing rates and postherpetic neuralgia (PHN), 2) the efficacy of ARYS-01 cream 3% vs. Placebo cream, prior to initiation of Valaciclovir, to build evidence for monotherapy treatment benefit of ARYS-01 cream on the initial onset of Herpes Zoster symptoms, 3) the efficacy of ARYS-01 cream 3% vs. Placebo cream, with immediate or delayed initiation of Valaciclovir, for synergetic effects on the initial onset of Herpes Zoster symptoms.

The primary efficacy endpoint is the effect of ARYS-01 cream (with or without Valaciclovir) on the reduction of the crusting stage of VZV rash present at Day 8. Secondary endpoints include time to cessation of new lesion formation, and time to cessation of Zoster-associated pains, pain intensity, rash healing and size reduction, and lesion dissemination.

03

Conditions studied

  • Herpes Zoster
  • Postherpetic Neuralgia

Keywords

  • antiviral
  • herpes zoster
  • postherpetic neuralgia
  • varicella zoster virus
  • shingles
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 18 years of age
  • diagnosed with herpes zoster
  • confirmed for VZV with lesion swab at screening and subsequent PCR test.
  • for women of
  • be able to communicate with investigator and compliant

Exclusion criteria

Exclusion Criteria:

  • cytotoxic or drugs within 3 mos, 5-FU or its pro-drugs, tricyclic antidepressants, probenecid, topical or systemic antiviral drugs or immunomodulatory agents for viral infection
  • herpes zoster ophthalmicus
  • female patients who are pregnant and/or nursing or planning a pregnancy
  • congenital, acquired or -induced immunodeficiency, including
  • renal insufficiency or creatinine level >2mg/dL
  • clinical significant liver enzyme abnormalities and any other laboratory abnormalities determined by the screening lab
  • history of intolerance or to the cream components
  • current significant skin disease within affected dermatome
  • history of positive result for surface antigen, virus, or
  • current participation in another clinical drug research study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Placebo comparator
    1

    Placebo cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10

    Drug: placebo · Drug: valaciclovir

  • Active comparator
    2

    Placebo cream BID for 10 days and active valaciclovir caplets TID from days 1-10

    Drug: ARYS-01 (sorivudine) cream 3% or placebo cream · Drug: placebo · Drug: valaciclovir

  • Experimental
    3

    Active cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10

    Drug: ARYS-01 (sorivudine) cream 3% or placebo cream · Drug: placebo · Drug: valaciclovir

  • Other
    4

    Active cream BID for 10 days and active valaciclovir caplets TID from days 1-10

    Drug: ARYS-01 (sorivudine) cream 3% or placebo cream · Drug: valaciclovir

Interventions

  • DrugARYS-01 (sorivudine) cream 3% or placebo cream

    sorivudine cream 3% or placebo cream twice daily for 10 days

    Also known as: ARYS-01 cream 3%, sorivudine cream 3%, topical sorivudine 3%

  • Drugplacebo

    placebo cream and placebo valaciclovir

  • active valaciclovir

06

What researchers measure

Primary outcomes

  1. The effect of ARYS-01 (sorivudine) cream (with or without Valaciclovir) on the reduction of the crusting stage of VZV rash present at Day 8.

    Time frame: Day 8

Secondary outcomes

  1. The time to cessation of new lesion formation, and time to cessation of Zoster-associated pains, pain intensity, rash healing and size reduction, and lesion dissemination.

    Time frame: Day 4

07

Study locations

10 sites
  • ARYS-0701 Site 3
    Beverly Hills, California 90211, United States
  • ARYS-0701 Site 6
    Encino, California 91436, United States
  • ARYS-0701 Site 7
    Vista, California 92083, United States
  • ARYS-0701 Site 8
    Henderson, Nevada 89014, United States
  • ARYS-0701 Site 9
    Las Vegas, Nevada 89106, United States
  • ARYS-0701 Site 10
    New York, New York 10003, United States
  • ARYS-0701 Site 11
    New York, New York 10029, United States
  • ARYS-0701 Site 4
    New York, New York 10032, United States
  • ARYS-0701 Site 12
    Raleigh, North Carolina 27612, United States
  • ARYS-0701 Site 1
    Houston, Texas 77058, United States
08

References and documents

Publications

  • Satyaprakash AK, Tremaine AM, Stelter AA, Creed R, Ravanfar P, Mendoza N, Mehta SK, Rady PL, Pierson DL, Tyring SK. Viremia in acute herpes zoster. J Infect Dis. 2009 Jul 1;200(1):26-32. doi: 10.1086/599381. PubMed 19469706 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jun 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 3, 2008
Start
Mar 2008
Primary completionEst.
Jun 2009
CompletionEst.
Sep 2009
Last update
Oct 7, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00652184
Lead sponsor
aRigen Pharmaceuticals, Inc.
First posted
Apr 3, 2008
Start date
Mar 2008
Primary completion
Jun 2009 (estimated)
Completion
Sep 2009 (estimated)
Last update
Oct 7, 2008

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valacyclovir

Start the discussion